VAXIMM is developing oral T-cell immunotherapies for cancer patients. Its technology is based on first-in-class oral T-cell activators, using modified attenuated bacteria carrying a eukaryotic expression plasmid, which enables the targeting of tumor-related antigens, including personalized neoantigens.
Vaximm AG
Verified listing
-
Founded2008
-
Employees in Switzerland1-9
- Website
- Get directions
- Bookmark
- Share
- Report
- prev
- next